Ucello Therapeutics is a biotechnology company based in San Diego, CA and Chengdu, China focused on developing universal (allogeneic) CAR-T therapies. The company is powered by its proprietary universal CAR-T cell technology platform, CBT-X20. Ucello has developed several off-the-shelf cell therapy pipelines targeting solid tumors and hematologic malignancies, with lead asset AT19. The company plans to use recent funding to advance CBT-X20, progress pipeline programs including AT19 toward US and China IND filings, and build state-of-the-art GMP-ready clinical manufacturing facilities. Ucello is led by CEO Dr. Qiang Zou. It recently closed a Series A financing to support these development and manufacturing objectives.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2022